CD274 and non-small cell lung carcinoma: Recently, the PACIFIC trial demonstrated the efficacy of durvalumab, a human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), in patients with stage III NSCLC as a sequential treatment following standard concurrent chemoradiotherapy3,4.